$11.16
4.35% today
Nasdaq, Feb 28, 09:17 pm CET
ISIN
US4834971032
Symbol
KALV
Sector
Industry

KalVista Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation

KalVista Pharmaceuticals, Inc. Classifications & Recommendation:

Buy
100%

KalVista Pharmaceuticals, Inc. Price Target

Target Price $26.89
Price $10.69
Potential
Number of Estimates 9
9 Analysts have issued a price target KalVista Pharmaceuticals, Inc. 2026 . The average KalVista Pharmaceuticals, Inc. target price is $26.89. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 10 analysts: 10 Analysts recommend KalVista Pharmaceuticals, Inc. to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the KalVista Pharmaceuticals, Inc. stock has an average upside potential 2026 of . Most analysts recommend the KalVista Pharmaceuticals, Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Apr '24 2025
Estimates
Earnings Per Share $ -3.44 -3.58
3.30% 4.07%
P/E negative

2 Analysts have issued a KalVista Pharmaceuticals, Inc. forecast for earnings per share. The average KalVista Pharmaceuticals, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-3.58
Unlock
. This is
1.65% higher
Unlock
than earnings per share in the financial year 2024. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-3.50 3.85%
Unlock
, the lowest is
$-3.65 0.27%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-3.44 3.30%
2025
$-3.58 4.07%
Unlock
2026
$-2.88 19.55%
Unlock

P/E ratio

Current -2.94 28.64%
2025
-2.99 1.70%
Unlock
2026
-3.71 24.08%
Unlock

Current KalVista Pharmaceuticals, Inc. Upgrades & Downgrades Beta

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
JMP Securities Locked ➜ Locked Locked Jan 31 2025
TD Cowen Locked ➜ Locked Locked Jan 07 2025
B of A Securities Locked ➜ Locked Locked Dec 18 2024
Cantor Fitzgerald Locked ➜ Locked Locked Dec 09 2024
HC Wainwright & Co. Locked ➜ Locked Locked Dec 06 2024
Needham Locked ➜ Locked Locked Dec 05 2024
HC Wainwright & Co. Locked ➜ Locked Locked Oct 07 2024
Analyst Rating Date
Locked
JMP Securities: Locked ➜ Locked
Jan 31 2025
Locked
TD Cowen: Locked ➜ Locked
Jan 07 2025
Locked
B of A Securities: Locked ➜ Locked
Dec 18 2024
Locked
Cantor Fitzgerald: Locked ➜ Locked
Dec 09 2024
Locked
HC Wainwright & Co.: Locked ➜ Locked
Dec 06 2024
Locked
Needham: Locked ➜ Locked
Dec 05 2024
Locked
HC Wainwright & Co.: Locked ➜ Locked
Oct 07 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today